New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
13:28 EDTRVNCRevance Therapeutics pullback a buying opportunity, says Cowen
Cowen says that while the FDA draft guidance on upper facial lines was surprising, it believes Revance's protocol for RT001 will be found acceptable. The firm recommends adding to Revance positions following the recent pullback and keeps an Outperform rating on the stock with a $55 price target.
News For RVNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RVNC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use